{Reference Type}: Journal Article
{Title}: Total Lesion Glycolysis Levels as Predictive Indicators in Patients With Metastatic and Recurrent Breast Cancer Undergoing Endocrine Therapy With or Without CDK4/6 Inhibitor.
{Author}: Ozawa H;Higuchi T;Fujimoto Y;Bun A;Fukui R;Kanaoka H;Nagahashi M;Kitajima K;Yamakado K;Miyoshi Y;Ozawa H;Higuchi T;Fujimoto Y;Bun A;Fukui R;Kanaoka H;Nagahashi M;Kitajima K;Yamakado K;Miyoshi Y;Ozawa H;Higuchi T;Fujimoto Y;Bun A;Fukui R;Kanaoka H;Nagahashi M;Kitajima K;Yamakado K;Miyoshi Y;
{Journal}: Anticancer Res
{Volume}: 42
{Issue}: 10
{Year}: Oct 2022
{Factor}: 2.435
{DOI}: 10.21873/anticanres.15986
{Abstract}: <B>OBJECTIVE: </B>Endocrine therapy (ET) with or without CDK4/6 inhibitors is the primary treatment choice for patients with estrogen receptor (ER)-positive and HER2-negative subtype of metastatic breast cancer (MBC). We examined the metabolic parameters identified using 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) in terms of sensitivity, since no predictive factors exist.<BR><B>METHODS: </B>We included 136 patients with MBC treated with ET alone (n=107) or combined with CDK4/6 inhibitor (n=29) and examined using FDG-PET before treatment began. The highest maximum value of the standard uptake value (SUVmax), whole-body metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were calculated.<BR><B>RESULTS: </B>Progression-free survival (PFS) was significantly longer in patients with low levels of MTV, TLG, and SUVmax than those with higher levels (median PFS 49.5 vs. 20.7 months, p=0.001 for MTV, 49.5 vs. 20.7 months, p=0.0016 for TLG, 37.0 vs. 20.7 months, p=0.012 for SUVmax). Multivariable analysis revealed that TLG (hazard ratio=6.383, 95% confidence interval=1.167-34.913, p=0.033) was independently and significantly associated with PFS. The relationship between TLG levels and PFS was significant in patients treated with ET with (p=0.0054) and without (p=0.0188) CDK4/6 inhibitor.<BR><B>CONCLUSIONS: </B>TLG at baseline was a significant predictor for sensitivity to ET alone or combined with CDK4/6 inhibitor. These data may be useful to identify patients that would benefit from ET.